Segment and Geographic Information

6 Months Ended

Jun. 30, 2017

The Company manages its business and operations as one segment and is focused on advancing the treatment of acute and intensive care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company allocates resources and assesses financial performance on a consolidated basis. Revenues reported below are derived primarily from sales of Angiomax in the United States, including royalty revenue from Sandoz.

The geographic segment information provided below is classified based on the major geographic regions in which the Company operates. Long-lived assets are comprised of the Company’s noncurrent assets.



	Three Months Ended June 30,								Six Months Ended June 30,
	2017				2016				2017				2016
	($ in thousands)
Net revenues:
United States	$	17,446	93.1	%	$	51,267	93.7	%	$	39,602	92.2	%	$	97,611	92.9	%
Europe	1,252		6.7	%	2,738		5.0	%	3,147		7.3	%	5,818		5.5	%
Rest of world	44		0.2	%	726		1.3	%	209		0.5	%	1,608		1.6	%
Total net revenues	$	18,742	100	%	$	54,731	100.0	%	$	42,958	100.0	%	$	105,037	100.0	%



	June 30, 2017				December 31, 2016
	($ in thousands)
Long-lived assets:
United States	$	712,152	99.6	%	$	1,047,098	99.6	%
Europe	2,929		0.4	%	4,160		0.4	%
Total long-lived assets	$	715,081	100.0	%	$	1,051,258	100.0	%